Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

Summary

This phase II trial studies how well alisertib works in treating patients with leiomyosarcoma of the uterus that has come back or persistent. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2012-08

Primary completion

2014-08

Completion

2017-02-11

Drugs

Indications